Product Name: CD45RA Antibody [SPM568]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC
Applications: Flow Cytometry: 0.5-1 ug/million cellsImmunofluorescence: 1-2 ug/mlImmunohistology (FFPE): 0.5-1.0 ug/ml for 30 minutes at RT (1)Prediluted format : incubate for 30 min at RT (2)Due to variation in protocol and secondary antibody used, the anti-CD45RA antibody may need to be titered for optimal performance.1. FFPE staining requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Stimulated human leukocytes were used as immunogen for this anti-CD45RA antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 654671-78-0
Product: Sitagliptin (phosphate)
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: Receptor-type tyrosine-protein phosphatase C, Leukocyte common antigen, L-CA, T200, CD45, PTPRC, CD45
Accession NO.:
Protein Ino:
Official Symbol: PTPRC
Geneid: 5788
Background: CD45RA is an isoform of the human leukocyte common antigen (CD45). Human CD45 contains three exons which encode peptide segments designated A, B and C, respectively. The differential splicing of the exons generates at least five isoforms, ABC, AB, BC, B and O. This antibody reacts with ABC and BC isoforms. CD45RA is expressed on 40-50% of peripheral CD4+ T-cells, 50% of peripheral CD8+ T-cells, B-cells, and leukemic B-cell lines. T-cells expressing CD45RA are naive or virgin T-cells. T-cells expressing CD45RO are memory T-cells. CD45RA and CD45RO define complementary, predominantly non-overlapping populations of resting peripheral T-cells. This MAb is useful in study on the subpopulation of CD4+ or CD8+ T-cells. It can especially be used to differentiate T-cell lymphomas (CD45RO +ve) from B cell lymphomas (CD45RA +ve).
PubMed ID:http://aac.asm.org/content/34/11/2277.abstract
